Full Library
Evaluation of intravenous voriconazole in patients with compromised renal function
Resource type
Journal Article
Authors/contributors
- Lilly, Craig M. (Author)
- Welch, Verna L. (Author)
- Mayer, Thomas (Author)
- Ranauro, Paul (Author)
- Meisner, Joanne (Author)
- Luke, David R. (Author)
Title
Evaluation of intravenous voriconazole in patients with compromised renal function
Abstract
Incorporation of the solubilizing excipient, sulfobutylether-β-cyclodextrin (SBECD), in the intravenous (IV) formulation of voriconazole has resulted in the recommendation that this formulation be used with caution in patients with creatinine clearances (Clcr) < 50 mL/min. This study evaluated the safety of IV voriconazole compared with two other IV antifungals not containing SBECD in patients with compromised renal function.
Publication
BMC Infectious Diseases
Date
January 16, 2013
Volume
13
Issue
1
Pages
14
Journal Abbr
BMC Infectious Diseases
Accessed
11/1/18, 11:22 AM
ISSN
1471-2334
Library Catalog
BioMed Central
Citation
Lilly, C. M., Welch, V. L., Mayer, T., Ranauro, P., Meisner, J., & Luke, D. R. (2013). Evaluation of intravenous voriconazole in patients with compromised renal function. BMC Infectious Diseases, 13(1), 14. https://doi.org/10.1186/1471-2334-13-14
DRUGS AND THERAPIES
Link to this record